https://www.selleckchem.com/products/pf-9366.html
0%). Immune-related AEs were common and included hypothyroidism (14.3%) and pneumonitiss (9.5%). No drug related deaths occurred. Conclusion This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas. © 2020 Tian et al.Purpose NPC is a malignant and invasive tumor with the incidence rate
Like
Comment
Share
